Scarica l'app Stockscreener
2.12
0.00%
0.00
Pre-mercato:
2.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$2.12
Aprire:
$2.15
Volume 24 ore:
3.72M
Relative Volume:
0.42
Capitalizzazione di mercato:
$640.04M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-1.4133
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-8.62%
1M Prestazione:
+31.68%
6M Prestazione:
+76.67%
1 anno Prestazione:
+8.16%
Intervallo 1D:
$2.06
$2.17
Intervallo di 1 settimana:
$2.06
$2.47
Portata 52W:
$0.8511
$2.725
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.12 | 640.04M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
128.47 | 218.16B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.19 | 137.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.31 | 135.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.57 | 128.03B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.38 | 48.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Barclays Maintains Rating and Increases Price Target for PACB | PACB Stock News - GuruFocus
Barclays Issues Positive Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price - MarketBeat
Amiral Gestion Invests $3.21 Million in Pacific Biosciences of California, Inc. $PACB - MarketBeat
Market Participants Recognise Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Revenues Pushing Shares 32% Higher - 富途牛牛
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 5.3%Here's What Happened - MarketBeat
Pacific Biosciences accelerates sequencing with HiFi advancements - Traders Union
Aug Swings: How Pacific Biosciences of California Inc stock reacts to Fed rate cutsJuly 2025 Breakouts & Fast Moving Stock Trade Plans - moha.gov.vn
EPS Watch: How Pacific Biosciences of California Inc stock valuations compare to rivalsStop Loss & Reliable Trade Execution Plans - moha.gov.vn
Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.8%Should You Sell? - MarketBeat
Pacific Biosciences of California Inc Stock Analysis and ForecastOptions Trading Strategies & Affordable Market Strategies - earlytimes.in
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S Is Still On The Mark Following 26% Share Price Bounce - simplywall.st
Geode Capital Management LLC Increases Position in Pacific Biosciences of California, Inc. $PACB - MarketBeat
Is Pacific Biosciences of California Inc. stock oversold or undervaluedJuly 2025 Rallies & Safe Swing Trade Setup Alerts - Newser
How Pacific Biosciences of California Inc. (P09) stock reacts to Fed tighteningEarnings Overview Summary & Weekly Top Stock Performers List - Newser
Is Pacific Biosciences of California Inc. (P09) stock undervalued historicallyWeekly Trend Recap & Community Trade Idea Sharing Platform - Newser
Will Pacific Biosciences of California Inc. (P09) stock beat revenue estimates2025 Retail Activity & Long-Term Safe Investment Plans - Newser
Why PacBio (PACB) Stock Is Up Today - Yahoo Finance
Pacific Biosciences (PACB) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Pacific Biosciences of California advances RNA sequencing in lung cancer research - Traders Union
Buy Signal: Will Pacific Biosciences of California Inc stock maintain dividend yieldJuly 2025 Price Swings & AI Forecasted Entry and Exit Points - BỘ NỘI VỤ
Does Pacific Biosciences of California Inc. (P09) stock trade below intrinsic valueMarket Risk Summary & Fast Moving Market Watchlists - Newser
Why Pacific Biosciences of California Inc. (P09) stock remains top rated2025 Earnings Impact & Fast Moving Trade Plans - Newser
How higher bond yields impact Pacific Biosciences of California Inc. (P09) stockJuly 2025 Market Mood & Safe Swing Trade Setups - Newser
XTX Topco Ltd Has $1.18 Million Stock Holdings in Pacific Biosciences of California, Inc. $PACB - MarketBeat
PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference - marketscreener.com
PacBio (NASDAQ: PACB) schedules fireside chat at Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Is Pacific Biosciences of California Inc. stock safe for conservative investorsMarket Activity Summary & Low Drawdown Investment Strategies - moha.gov.vn
How Recent Moves Are Rewriting the Story for PacBio Amid Shifting Analyst Sentiment - Yahoo Finance
Pacific Biosciences of California Insiders Made A Wise Decision By Selling US$864k Worth Of Stock - simplywall.st
Pullback Watch: Is Pacific Biosciences of California Inc. stock cheap compared to fundamentalsPortfolio Value Report & Real-Time Stock Entry Alerts - moha.gov.vn
Pacific Biosciences of California, Inc.Common Stock (NQ: PACB - Markets Financial Content
How risky is Pacific Biosciences of California Inc. stock now2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
PACB Shares Climb as Market Adjusts to New Forecasts - timothysykes.com
Pacific Biosciences of California, Inc. $PACB Shares Sold by Edmond DE Rothschild Holding S.A. - MarketBeat
Pacific Biosciences of California: HiFi sequencing resolves genome complexities - Traders Union
Pacific Biosciences stock delivers 70% return after InvestingPro’s undervalued call By Investing.com - Investing.com Australia
Pacific Biosciences of California (NASDAQ:PACB) Hits New 52-Week HighWhat's Next? - MarketBeat
PacBio, Bristol-Myers Squibb, Oscar Health, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know - Finviz
PacBio Gains Traction with New Sequel II CNDx Approval in China - StocksToTrade
PacBio’s Strategic Steps: China’s Approval and HiFi Sequencing Insights Boost Confidence - timothysykes.com
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
What analysts say about Pacific Biosciences of California Inc P09 stockRetail Trading Trends & Low Entry Cost Capital - earlytimes.in
PacBio Stock May Gain Following the Collaborated Launch of GutID - MSN
What analysts say about Pacific Biosciences of California Inc stock - earlytimes.in
Can Dev Information Technology Limited Outperform Peers After Recent PullbackMarket Depth Overview & Low Risk Investment Tips - earlytimes.in
PacBio Stock Soars: Time to Dive In? - StocksToTrade
Pacific Biosciences of California launches HiFi guide to enhance lab workflows - Traders Union
PacBio’s Regulatory Triumph in China Fuels Market Optimism - timothysykes.com
$PACB stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
PacBio’s New Regulatory Approval Fuels Expansion Hopes - timothysykes.com
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.42%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):